

Determination of fatty acid and triacylglycerol composition of human very-low-density lipoproteins

V. Ruíz-Gutiérrez*

Instituto de la Grasa y sus Derivados, Apdo. 1078, 41012 Sevilla (Spain)

J.L. Prada and F. Pérez-Jiménez

Unidad de Lípidos, Hospital Universitario Reina Sofía, Córdoba (Spain)

(First received June 11th, 1993; revised manuscript received September 20th, 1993)

ABSTRACT

The fatty acid composition of human very-low-density lipoproteins (VLDL) was studied in a population from western Andalusia with a diet in which the fat content came mainly from olive oil. The lipid composition of VLDL, including the fatty acid composition of the phospholipids and triacylglycerols, was examined by capillary gas chromatography. Twenty-five peaks were resolved, ranging in chain length from 14 to 24 carbon atoms, including geometric and positional isomers. The major fatty acids present in phospholipids were 16:0, 18:0, 18:1(*n* – 9) and 18:2(*n* – 6), and in triacylglycerols were 18:1(*n* – 9), 16:0 and 18:2(*n* – 6). The major triacylglycerol was POO, followed by PLO and OOO. MLP, PPS and LLL were absent. The presence of a large amount of OOO in this fraction demonstrates that the triacylglycerol composition of the VLDL depends on the type of diet consumed.

INTRODUCTION

Because lipids are insoluble in water, they must form molecular aggregates with proteins in order to be transported in the blood. These aggregates are the lipoproteins.

The very-low-density lipoproteins (VLDL) constitute a family of lipoproteins with a significant degree of variability in terms of their size, density and chemical composition. Generally, they have a diameter between 25 and 70 nm, a density between 0.95 and 1.006 g/ml and a molecular mass between $5 \cdot 10^6$ and $10 \cdot 10^6$. VLDL are formed by a non-polar core consisting mainly of cholesterol esters and triacylglycerols. After their synthesis in the liver, triglycerides

predominate in the core [1], but as catabolism progresses and their diameter decreases, the principal components of this hydrophobic nucleus are the cholesterol esters [2]. The apolipoprotein of the VLDL present in the highest proportions is apo-B100, which represents from 30% to 50% of the total protein content of the particle. Significant amounts of apo-C and apo-E are also present, although the amounts depend on the metabolic stage of the particle [3].

The VLDL are formed in the liver from the cholesterol and fatty acids that enter it, as well as from those synthesized in this organ. Once in the plasma, the particle undergoes a process of maturation, consisting of a gain of apolipoprotein C proceeding from the HDL. By this means its structure becomes adapted for interaction with lipoproteinlipase (LPL) [4], the enzyme responsible for its degradation. While some of its

* Corresponding author.

Blood sampling and biochemical determinations

Blood samples from fasting subjects were taken at the end of the experimental period by venipuncture into tubes containing EDTA (1 mg/ml). Tubes were immediately placed in ice, and plasma was separated by low-speed centrifugation within 1 h of sampling. Lipid apolipoprotein analysis was performed within 24 h.

Lipoprotein fractions were isolated from fresh plasma samples by sequential ultracentrifugation [11] using a Beckman Model L5 ultracentrifuge with a Type 5 rotor (Beckman, Fullerton, CA, USA). VLDL were separated by ultracentrifugation for 20 h at 105 000 *g* at a temperature of 4°C.

Standards

Fatty acid methyl ester (FAME) standards were obtained from Larodan Fine Chemicals (Malmo, Sweden). The internal standard solution was prepared by dissolving 200 mg of tricosanoic acid methyl ester (C23:0) in 100 ml of hexane. The calibration solutions were prepared by dissolving known amounts of FAME standards in hexane containing 2,6-di-*tert*-butyl-*p*-cresol (butylated hydroxy toluene, BHT) obtained from Sigma (Poole, UK).

Apparatus

For sequential ultracentrifugation a type 50 rotor and an L5-50 ultracentrifuge (Beckman, Fullerton, CA, USA) were used.

The FAMEs thus obtained were eluted with hexane and analysed in a Hewlett-Packard 5890 series II gas chromatograph equipped with a flame ionization detector and an Omegawax 320 fused-silica capillary column (30 m \times 0.32 mm I.D., 0.25 μ m film), obtained from Supelco (Bellafonte, PA, USA).

Mass spectral data were obtained with an automated gas chromatographic-mass spectrometric (GC-MS) system, composed of an HP-5890 gas chromatograph interfaced directly to an AEI MS-30 VG/70 update mass spectrometer and a VG-11/250 data system (VG Analytical, Manchester, UK).

Triacylglycerol analysis was carried out using a Chrompack CP 9000 gas chromatograph (Chrompack International, Middleburg, Nether-

lands) fitted with a split injector and a flame ionization detector.

Plasma biochemical determinations

Levels of glucose, total and VLDL cholesterol, total and VLDL triglycerides and total and VLDL phospholipids were determined in venous blood from fasting subjects by standard enzymatic procedures (Boehringer Mannheim, Mannheim, Germany) with an Hitachi Model 705 automatic analyser, using Precilip and Precilip EL (Boehringer Mannheim) as quality controls.

Lipid extraction

Quantitative extraction of total lipids from VLDL was carried out following the method of Folch *et al.* [12].

Separation and quantification of lipids

Neutral lipids from the VLDL were separated by thin-layer chromatography (TLC) on plates of silica gel 60 (Kieselgel 60 F₂₅₄, Merck) using a solvent system of hexane-diethyl ether-acetic acid (80:20:1, v/v/v). After development, the solvent was allowed to evaporate. This system separates phospholipids, cholesterol, triacylglycerols and cholesterol esters in increasing order of R_F . Individual lipid zones were scraped from the TLC plates and eluted from the silica gel with either diethyl ether or chloroform-methanol, depending on the individual lipids.

The VLDL lipid classes were quantified following their separation on thin silica-coated quartz rods (Chromarod S) using an Iatroscan (Technical Marketing Associates, Mississauga, Ont., Canada) equipped with a flame ionization detector (hydrogen flow-rate, 175 ml/min; air flow-rate, 1850 ml/min), a scanner (scanning speed, 0.47 cm/s) and an integrator and recorder (sensitivity, 10 mV; chart speed, 0.42 cm/min). The Chromarods (type S9) were successively developed using hexane-diethyl ether-formic acid (90:10:3, v/v/v).

Preparation of FAMES

Lipids were transmethylated according to the method of Morrison and Smith [13]. The lipid bands on plates of silica gel 60 were sprayed

TABLE IV
FATTY ACID COMPOSITION OF PHOSPHOLIPIDS
AND NEUTRAL LIPIDS OF HUMAN VLDL


Fatty acid	Composition (mean \pm S.D.) (%, w/w)	
	Phospholipids	Triacylglycerol
14:0	0.71 \pm 0.46	1.07 \pm 0.02
16:0	30.35 \pm 4.14	24.37 \pm 1.43
16:1(<i>n</i> - 7)	0.14 \pm 0.12	1.49 \pm 0.02
16:1(<i>n</i> - 9)	0.35 \pm 0.64	1.93 \pm 0.37
16:4(<i>n</i> - 3)	0.88 \pm 0.58	0.11 \pm 0.01
18:0	17.04 \pm 1.17	2.52 \pm 0.36
18:1(<i>n</i> - 9)	16.28 \pm 2.3	42.30 \pm 0.22
18:1(<i>n</i> - 7)	1.81 \pm 0.27	2.53 \pm 0.21
18:1 <i>trans</i>	0.18 \pm 0.15	—
18:2(<i>n</i> - 6)	14.84 \pm 1.74	20.36 \pm 3.22
18:3(<i>n</i> - 3)	0.83 \pm 0.63	0.48 \pm 0.10
18:4(<i>n</i> - 3)	0.28 \pm 0.20	—
20:0	0.26 \pm 0.11	0.16 \pm 0.01
20:1(<i>n</i> - 11)	0.11 \pm 0.02	—
20:1(<i>n</i> - 9)	0.21 \pm 0.09	0.35 \pm 0.02
20:2(<i>n</i> - 6)	0.15 \pm 0.07	—
20:3(<i>n</i> - 6)	2.45 \pm 0.74	—
20:4(<i>n</i> - 6)	5.82 \pm 2.17	1.04 \pm 0.01
20:4(<i>n</i> - 3)	2.1 \pm 1.87	—
20:5(<i>n</i> - 3)	0.44 \pm 0.32	—
22:1(<i>n</i> - 11)	0.35 \pm 0.34	—
22:5(<i>n</i> - 6)	1.39 \pm 1.64	—
22:5(<i>n</i> - 3)	0.43 \pm 0.17	0.21 \pm 0.04
22:6(<i>n</i> - 3)	2.57 \pm 0.79	0.67 \pm 0.03
24:1(<i>n</i> - 9)	0.04 \pm 0.02	0.11 \pm 0.02
Σ Saturated	48.36	28.12
Σ Mono-unsaturated	19.48	48.71
Σ Poly-unsaturated	32.18	22.87
Σ <i>n</i> - 3	7.53	1.47
Σ <i>n</i> - 6	24.65	21.4
Σ <i>n</i> - 9	16.88	44.69
Σ <i>n</i> - 6/ Σ <i>n</i> - 3	3.27	14.56
Σ <i>n</i> - 9/ Σ <i>n</i> - 3	2.24	30.4

50% of the total, while the mono-unsaturated fatty acids never represent more than 20%. In the triacylglycerols, however, the most important group are the mono-unsaturated fatty acids, which constitute almost half of the total, the remaining fatty acids being saturated and polyunsaturated fatty acids in equal parts. In the phospholipids, the most important group of fatty acids is that formed by the $n-6$ fatty acids, whereas in the triacylglycerols the $n-9$ fatty acids account for almost half of the fatty acids,

The fatty acid profile of polar and neutral lipids of human VLDL can be seen in Table IV. The major fatty acids present in the phospholipids were palmitic (16:0), stearic (18:0), oleic (18:1 *n* - 9) and linoleic (18:2 *n* - 6) acids. Triacylglycerols contained the largest amount of oleic acid (18:1 *n* - 9), accounting for 42.4% of the triacylglycerol fatty acids, followed by palmitic (16:0) and linoleic (18:2 *n* - 6) acids. The fatty acid composition of the phospholipids was more diverse than that of the triacylglycerols. It can be seen that, in the phospholipids, eicosapentanoic (20:5 *n* - 3) and eicosanoic (20:1 *n* - 11) acids were identified. Although these fatty acids are typical of fish, they can sometimes be isolated from the polar fraction of mammalian tissue lipids. Their presence in the phospholipids studied here was undoubtedly due to the diet of the subjects, from which fish was not excluded at any point. It is similarly beyond doubt that these fatty acids present in the phospholipids of the VLDL were destined to form part of the cell membranes.

Arachidonic acid (20:4 $n-6$) deserves special attention, because it is the precursor of the prostaglandins and of the leucotrienes. It was detected in significant amounts (*ca.* 6%) in the phospholipids, whereas in the triacylglycerols it never represented more than 1%. The presence of this acid, together with that of docosahexanoic acid (22:6 $n-3$) is especially significant. Both of these were detectable only in the phospholipid fraction of the VLDL. If we examine the overall fatty acid composition, it is clear that the saturated fatty acids constitute the most abundant type in the phospholipids, making up almost

different diets. For example, studies performed on Canadian populations [16,17] demonstrate that these populations differ substantially in the composition of their TGs. In addition, in the Andalusian population examined in the present study, the percentages of POO and PLO are significantly higher than those in the Canadian population [16]. Furthermore, the most important aspect of the comparison between these two studies is the highly significant difference in the concentration of triolein, which in the Andalusian population constituted 12.2% and in the



Canadian population 34%. This difference is undoubtedly due to the fact that in the population studied in the present work, the oil consumed in the diet is primarily olive oil, in which triolein is one of the major TGs. However, if we compare the TG composition determined in the present work with a previous study of a population from Andalusia [18], it can be seen that the TG composition of human tissue is similar, in terms of the major TGs present, to that of the VLDL lipoproteins found in the cited study. Examining the concentrations of the TGs present in lower amounts, however, and comparing them with the results from the previously-mentioned study [16] performed on adipose tissue, it can be seen that in the VLDL, MLP (glycerol-myristate-linoleate-palmitate), PPS and LLL are all absent. The absence of these triglycerides in the

ACKNOWLEDGEMENT

This work was supported by a grant from the Comisión Interministerial de Ciencia y Tecnología ALI 92-0881.

REFERENCES

- 1 D. Streja, M.A. Kallay and G. Steiner, *Metabolism*, 26 (1977) 1333.
- 2 D.V. Rajaram, G.H. White and P.J. Barter, *Biochim. Biophys. Acta*, 617 (1980) 383.
- 3 A. Rubinstein, J.C. Gibson, J.R. Paterniti Jr, G. Kakis, A. Little, H.N. Ginsberg and W.V. Brown, *J. Clin. Invest.*, 75 (1985) 710.
- 4 R.L. Jackson, S. Tajima, T. Yamura, S. Yokoyama and A. Yamamoto, *Biochim. Biophys. Acta*, 875 (1986) 211.
- 5 P. Sammet and A.R. Tall, *J. Biol. Chem.*, 260 (1985) 6687.
- 6 H. Jansen and W.C. Hulsman, *Biochem. Soc. Trans.*, 13 (1985) 24.
- 7 A. Keys, A. Menotti, M.J. Karvonen, C. Aravanis, H. Blackburn, R. Buzina, B.S. Djordjevic, A.S. Dontas, F. Fidanza, M.H. Keys, D. Kromhout, S. Nedeljkovic, S. Punsar, F. Seccareccia and H. Toshima, *Am. J. Epidemiol.*, 124 (1986) 903.
- 8 L.A. Simons, *Current Opinion in Lipidology*, 1 (1990) 23.
- 9 K. Bondrup, N. Koster, F. Quaade and H. Roseven, *Scand. J. Clin. Lab. Inves.*, 18 (1966) 588.
- 10 G.E. Andersen, N.C. Christensen, M.B.V. Petersen and K.B. Johansen, *Acta Paediatr. Scand.*, 76 (1987) 87.
- 11 V.N. Schumaker and D.L. Puppione, *Methods Enzymol.*, 128 (1986) 155.
- 12 J. Folch, M. Lees and G.H. Sloane-Staley, *J. Biol. Chem.*, 33 (1957) 497.
- 13 W.R. Morrison and L.D.S. Smith, *J. Lipid Res.*, 5 (1963) 600.
- 14 V. R  iz-Guti  rrez, A. Cert and J.J. R  os, *J. Chromatogr.*, 575 (1992) 1.

- 15 E. Geeraert, in A. Kuksis (Editor), *Chromatography of Lipids in Biomedical Research and Clinical Diagnosis*, Elsevier, Amsterdam, 1987, p. 48.
- 16 A. Kuksis, J.J. Myher and P. Sandra, *J. Chromatogr.*, 500 (1990) 427.
- 17 A. Kuksis, J.J. Myher and K. Ceher, *J. Lipid Res.*, 34 (1993) 1029.
- 18 V. Ruíz-Gutiérrez, E. Montero and J. Villar, *J. Chromatogr.*, 581 (1992) 171.